Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Envoy Medical (COCH) Research & Development (2022 - 2025)

Envoy Medical's Research & Development history spans 4 years, with the latest figure at $2.7 million for Q3 2025.

  • For Q3 2025, Research & Development fell 2.07% year-over-year to $2.7 million; the TTM value through Sep 2025 reached $10.7 million, down 0.68%, while the annual FY2023 figure was $9.0 million, 80.02% up from the prior year.
  • Research & Development for Q3 2025 was $2.7 million at Envoy Medical, up from $2.5 million in the prior quarter.
  • Across five years, Research & Development topped out at $3.1 million in Q4 2023 and bottomed at $1.4 million in Q4 2022.
  • The 4-year median for Research & Development is $2.5 million (2025), against an average of $2.4 million.
  • The largest annual shift saw Research & Development surged 111.71% in 2023 before it decreased 4.09% in 2025.
  • A 4-year view of Research & Development shows it stood at $1.4 million in 2022, then surged by 111.71% to $3.1 million in 2023, then dropped by 9.75% to $2.8 million in 2024, then dropped by 2.07% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for COCH's Research & Development are $2.7 million (Q3 2025), $2.5 million (Q2 2025), and $2.7 million (Q1 2025).